TY - JOUR
T1 - Location-dependent signaling of the group 1 metabotropic glutamate receptor mGlu5
AU - Jong, Yuh Jiin I.
AU - Sergin, Ismail
AU - Purgert, Carolyn A.
AU - O'Malley, Karen L.
N1 - Publisher Copyright:
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2014
Y1 - 2014
N2 - Although G protein-coupled receptors are primarily known for converting extracellular signals into intracellular responses, some receptors, such as the group 1 metabotropic glutamate receptor, mGlu5, are also localized on intracellular membranes where they can mediate both overlapping and unique signaling effects. Thus, besides "ligand bias," whereby a receptor's signaling modality can shift from G protein dependence to independence, canonical mGlu5 receptor signaling can also be influenced by "location bias" (i.e., the particular membrane and/or cell type from which it signals). Because mGlu5 receptors play important roles in both normal development and in disorders such as Fragile X syndrome, autism, epilepsy, addiction, anxiety, schizophrenia, pain, dyskinesias, and melanoma, a large number of drugs are being developed to allosterically target this receptor. Therefore, it is critical to understand how such drugs might be affecting mGlu5 receptor function on different membranes and in different brain regions. Further elucidation of the site(s) of action of these drugs may determine which signal pathways mediate therapeutic efficacy.
AB - Although G protein-coupled receptors are primarily known for converting extracellular signals into intracellular responses, some receptors, such as the group 1 metabotropic glutamate receptor, mGlu5, are also localized on intracellular membranes where they can mediate both overlapping and unique signaling effects. Thus, besides "ligand bias," whereby a receptor's signaling modality can shift from G protein dependence to independence, canonical mGlu5 receptor signaling can also be influenced by "location bias" (i.e., the particular membrane and/or cell type from which it signals). Because mGlu5 receptors play important roles in both normal development and in disorders such as Fragile X syndrome, autism, epilepsy, addiction, anxiety, schizophrenia, pain, dyskinesias, and melanoma, a large number of drugs are being developed to allosterically target this receptor. Therefore, it is critical to understand how such drugs might be affecting mGlu5 receptor function on different membranes and in different brain regions. Further elucidation of the site(s) of action of these drugs may determine which signal pathways mediate therapeutic efficacy.
UR - http://www.scopus.com/inward/record.url?scp=84964698932&partnerID=8YFLogxK
U2 - 10.1124/mol.114.094763
DO - 10.1124/mol.114.094763
M3 - Short survey
C2 - 25326002
AN - SCOPUS:84964698932
SN - 0026-895X
VL - 86
SP - 774
EP - 785
JO - Molecular pharmacology
JF - Molecular pharmacology
IS - 6
ER -